Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study
Abstract Background High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum. The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received c...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2019-09-01
|
| Series: | Diagnostic Pathology |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13000-019-0885-2 |
| _version_ | 1818017222154518528 |
|---|---|
| author | Marina Piljić Burazer Suzana Mladinov Antonela Matana Sendi Kuret Joško Bezić Merica Glavina Durdov |
| author_facet | Marina Piljić Burazer Suzana Mladinov Antonela Matana Sendi Kuret Joško Bezić Merica Glavina Durdov |
| author_sort | Marina Piljić Burazer |
| collection | DOAJ |
| description | Abstract Background High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum. The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received chemotherapy based on platinum. Material/methods A total of 253 lung adenocarcinoma patients in all TNM stages were retrospectively investigated. The diagnosis was based on small biopsy samples obtained during bronchoscopy. Depending on the TNM stage of the disease and clinical condition, patients received only the chemotherapy based on platinum, or in combination with radiotherapy or surgery. Tissue sample for ERCC1 immunohistochemical analysis was sufficient in 129 patients. Low from high ERCC1 expression was separated by the semi-quantitative H-score median. Results High ERCC1 expression was found in 47.3% patients, and was correlated with higher TNM (p = 0.021), tumor enlargement (p = 0.002), positive lymph nodes (p = 0.001), positive distant metastasis (p = 0.005), and higher relative risk of death (p < 0.001). Furthermore, significance association was observed for low ERCC1 expression and better performance status (ECOG) (p = 0.023). Longer OS was strongly associated with a low ERCC1 expression, not only in the group of patients in TNM stage I-III, who were treated with combination of chemotherapy with surgery or radiotherapy (p = 0.002), but also in the group of patients in TNM stage IV who received only chemotherapy based on platinum (p < 0.001), compared with the patients in the same TNM stage and high ERCC1 expression. Conclusions ERCC1 expression in lung adenocarcinoma is a useful prognostic marker and moreover, a useful predictive marker in patients receiving chemotherapy based on platinum in all stages of the disease. |
| first_indexed | 2024-04-14T07:24:31Z |
| format | Article |
| id | doaj.art-4cc02fd6ad8f4accbf0bed2b6ef9d9a7 |
| institution | Directory Open Access Journal |
| issn | 1746-1596 |
| language | English |
| last_indexed | 2024-04-14T07:24:31Z |
| publishDate | 2019-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Diagnostic Pathology |
| spelling | doaj.art-4cc02fd6ad8f4accbf0bed2b6ef9d9a72022-12-22T02:06:03ZengBMCDiagnostic Pathology1746-15962019-09-011411810.1186/s13000-019-0885-2Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center studyMarina Piljić Burazer0Suzana Mladinov1Antonela Matana2Sendi Kuret3Joško Bezić4Merica Glavina Durdov5Institutet of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center SplitDepartment of Pulmonology, Clinical Hospital Center SplitDepartment of Medical Biology, University of Split, School of MedicineInstitutet of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center SplitInstitutet of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center SplitInstitutet of Pathology, Forensic Medicine and Cytology, Clinical Hospital Center SplitAbstract Background High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum. The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received chemotherapy based on platinum. Material/methods A total of 253 lung adenocarcinoma patients in all TNM stages were retrospectively investigated. The diagnosis was based on small biopsy samples obtained during bronchoscopy. Depending on the TNM stage of the disease and clinical condition, patients received only the chemotherapy based on platinum, or in combination with radiotherapy or surgery. Tissue sample for ERCC1 immunohistochemical analysis was sufficient in 129 patients. Low from high ERCC1 expression was separated by the semi-quantitative H-score median. Results High ERCC1 expression was found in 47.3% patients, and was correlated with higher TNM (p = 0.021), tumor enlargement (p = 0.002), positive lymph nodes (p = 0.001), positive distant metastasis (p = 0.005), and higher relative risk of death (p < 0.001). Furthermore, significance association was observed for low ERCC1 expression and better performance status (ECOG) (p = 0.023). Longer OS was strongly associated with a low ERCC1 expression, not only in the group of patients in TNM stage I-III, who were treated with combination of chemotherapy with surgery or radiotherapy (p = 0.002), but also in the group of patients in TNM stage IV who received only chemotherapy based on platinum (p < 0.001), compared with the patients in the same TNM stage and high ERCC1 expression. Conclusions ERCC1 expression in lung adenocarcinoma is a useful prognostic marker and moreover, a useful predictive marker in patients receiving chemotherapy based on platinum in all stages of the disease.http://link.springer.com/article/10.1186/s13000-019-0885-2Lung adenocarcinomaERCC1Platinum-based chemotherapy |
| spellingShingle | Marina Piljić Burazer Suzana Mladinov Antonela Matana Sendi Kuret Joško Bezić Merica Glavina Durdov Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study Diagnostic Pathology Lung adenocarcinoma ERCC1 Platinum-based chemotherapy |
| title | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study |
| title_full | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study |
| title_fullStr | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study |
| title_full_unstemmed | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study |
| title_short | Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study |
| title_sort | low ercc1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all tnm stages a single center study |
| topic | Lung adenocarcinoma ERCC1 Platinum-based chemotherapy |
| url | http://link.springer.com/article/10.1186/s13000-019-0885-2 |
| work_keys_str_mv | AT marinapiljicburazer lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy AT suzanamladinov lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy AT antonelamatana lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy AT sendikuret lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy AT joskobezic lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy AT mericaglavinadurdov lowercc1expressionisagoodpredictivemarkerinlungadenocarcinomapatientsreceivingchemotherapybasedonplatinuminalltnmstagesasinglecenterstudy |